β-Blockers in Hepatosplenic Schistosomiasis: A Narrative Review
- PMID: 37931294
- PMCID: PMC10793037
- DOI: 10.4269/ajtmh.23-0437
β-Blockers in Hepatosplenic Schistosomiasis: A Narrative Review
Abstract
Hepatosplenic schistosomiasis (HSS) is a serious complication of chronic schistosomiasis that can result in portal hypertension and variceal bleeding. β-blockers, a class of medications commonly used to treat hypertension and other cardiovascular conditions, have been investigated for their potential use in preventing variceal bleeding in HSS. Several studies have shown that β-blockers can reduce portal pressure and prevent variceal bleeding effectively in these patients. However, there are limited data on the long-term efficacy and safety of β-blockers in this setting, and further research is needed to determine the optimal use of these medications. This review summarizes the evidence supporting current recommendations of β-blocker use in patients with HSS.
References
-
- World Health Organization , 2021. Ending the Neglect to Attain the Sustainable Development Goals: A Road Map for Neglected Tropical Diseases 2021–2030. Available at: https://www.who.int/publications/i/item/9789240010352. Accessed May 12, 2023.
-
- World Health Organization , 2013. Schistosomiasis: Progress Report 2001–2011, Strategic Plan 2012–2020. Available at: https://apps.who.int/iris/handle/10665/78074. Accessed May 12, 2023.
-
- Institute for Health Metrics and Evaluation , 2019. Schistosomiasis: Level 3 Cause. Available at: https://www.healthdata.org/results/gbd_summaries/2019/schistosomiasis-le.... Accessed March 31, 2023.
-
- Gunda DW, Kilonzo SB, Manyiri PM, Peck RN, Mazigo HD, 2020. Morbidity and mortality due to Schistosoma mansoni related periportal fibrosis: could early diagnosis of varices improve the outcome following available treatment modalities in sub Saharan Africa? A scoping review. Trop Med Infect Dis 5: 20. - PMC - PubMed
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical